Literature DB >> 20922574

Treatment of colorectal cancer with unresectable synchronous liver-only metastases with combined therapeutic modalities.

Yunlong Cui1, Huikai Li, Qiang Wu, Ti Zhang, Dalu Kong, Tianqiang Song, Tao Ru, Ping Chen, Qiang Li.   

Abstract

BACKGROUND: Resection + radiofrequency ablation (RFA) + hepatic artery infusion (HAI) + systemic chemotherapy for patients with unresectable synchronous liver-only metastases from colorectal cancer was rarely used previously.
METHODS: We compared the outcomes of 42 patients underwent resection + RFA + HAI + systemic chemotherapy (RRHS) with that of 43 patients underwent resection + RFA + systemic chemotherapy (RRS).
RESULTS: The overall survival, the survival free of hepatic recurrence and the median survival in the RRHS group were all significantly higher than those in RRS group at 4 years. While the rates of adverse effects were similar in the two groups.
CONCLUSION: For patients with unresectable synchronous liver-only metastases from colorectal cancer, RRHS not only decreases but also postpones hepatic recurrence and therefore improves overall survival at 4 years, as compared with RRS.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20922574     DOI: 10.1007/s11605-010-1357-x

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  18 in total

1.  Hepatic arterial infusion after liver resection.

Authors:  Nancy E Kemeny; Mithat Gonen
Journal:  N Engl J Med       Date:  2005-02-17       Impact factor: 91.245

2.  Phase I and pharmacokinetic study of hepatic arterial infusion with oxaliplatin in combination with folinic acid and 5-fluorouracil in patients with hepatic metastases from colorectal cancer.

Authors:  W Kern; B Beckert; N Lang; J Stemmler; M Beykirch; J Stein; E Goecke; T Waggershauser; J Braess; A Schalhorn; W Hiddemann
Journal:  Ann Oncol       Date:  2001-05       Impact factor: 32.976

3.  Trends in long-term survival following liver resection for hepatic colorectal metastases.

Authors:  Michael A Choti; James V Sitzmann; Marcelo F Tiburi; Wuthi Sumetchotimetha; Ram Rangsin; Richard D Schulick; Keith D Lillemoe; Charles J Yeo; John L Cameron
Journal:  Ann Surg       Date:  2002-06       Impact factor: 12.969

4.  Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481).

Authors:  Nancy E Kemeny; Donna Niedzwiecki; Donna R Hollis; Heinz-Josef Lenz; Robert S Warren; Michelle J Naughton; Jane C Weeks; Elin R Sigurdson; James E Herndon; Chunfeng Zhang; Robert J Mayer
Journal:  J Clin Oncol       Date:  2006-02-27       Impact factor: 44.544

5.  Cancer statistics, 2005.

Authors:  Ahmedin Jemal; Taylor Murray; Elizabeth Ward; Alicia Samuels; Ram C Tiwari; Asma Ghafoor; Eric J Feuer; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2005 Jan-Feb       Impact factor: 508.702

6.  Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases.

Authors:  Timothy M Pawlik; Charles R Scoggins; Daria Zorzi; Eddie K Abdalla; Axel Andres; Cathy Eng; Steven A Curley; Evelyne M Loyer; Andrea Muratore; Gilles Mentha; Lorenzo Capussotti; Jean-Nicolas Vauthey
Journal:  Ann Surg       Date:  2005-05       Impact factor: 12.969

7.  Sequential intrahepatic and systemic fluoropyrimidine-based chemotherapy for metastatic colorectal cancer confined to the liver. A phase II study.

Authors:  C Porta; M Danova; S Accurso; C Tinelli; M Girino; A Riccardi; S Palmeri
Journal:  Cancer Chemother Pharmacol       Date:  2001-05       Impact factor: 3.333

8.  Colorectal liver metastases: recurrence and survival following hepatic resection, radiofrequency ablation, and combined resection-radiofrequency ablation.

Authors:  Ana L Gleisner; Michael A Choti; Lia Assumpcao; Hari Nathan; Richard D Schulick; Timothy M Pawlik
Journal:  Arch Surg       Date:  2008-12

9.  Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure.

Authors:  Valérie Boige; David Malka; Dominique Elias; Marine Castaing; Thierry De Baere; Diane Goere; Clarisse Dromain; Marc Pocard; Michel Ducreux
Journal:  Ann Surg Oncol       Date:  2007-09-26       Impact factor: 5.344

10.  Role of intraoperative thermoablation combined with resection in the treatment of hepatic metastasis from colorectal cancer.

Authors:  Peter Kornprat; William R Jarnagin; Ronald P DeMatteo; Yuman Fong; Leslie H Blumgart; Michael D'Angelica
Journal:  Arch Surg       Date:  2007-11
View more
  1 in total

1.  Local tumor progression patterns after radiofrequency ablation of colorectal cancer liver metastases.

Authors:  Marc Napoleone; Ania Z Kielar; Rebecca Hibbert; Sameh Saif; Benjamin Y Kwan
Journal:  Diagn Interv Radiol       Date:  2016 Nov-Dec       Impact factor: 2.630

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.